Solvay Pharmaceuticals, Gmbh

Kali-chemie Pharma Gmbh

Abbott Products Gmbh

Michael Wurl

Jochen Antel

Harald Waldeck

Ulf Preuschoff

Uwe Schoen

Reiner Muller-Peddinghaus

Ivan Ban

Holger Sann

Dirk Thormaehlen

Dania B Reiche

Peter-Colin Gregory

Michael Firnges

Rainer Walenta

Peter Eickelmann

Reinhard Brueckner

Josef Messinger

Dagmar Hoeltje

Daniel Jasserand

Peter Colin Gregory

Joerg Meil

Uwe Reinecker

Sabine Eyting

Maike Wolff

Dania Reiche

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions. 

N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

4-substituted 1-amidomethylcarbonyl-piperidine compounds having motilin-agonistic properties and their acid addition salts, pharmaceutical compositions containing these compounds, processes and intermediate products for the preparation of these compounds, and methods of treatment utilizing these compounds.

1-amidomethylcarbonyl-piperidine compounds, methods and intermediate products for the production thereof and pharmaceutical formulations containing said compounds

N-sulfamoyl-N'-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions 

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

Substituted &#x3b2;-lactones (oxetanones) corresponding to the formula I, wherein R, Rand n have the meanings given in the specification, and pharmaceutical compositions which contain these compounds and have a pancreatic lipase-inhibiting action, as well as a process for the preparation of the compounds of Formula I and intermediate products of this process.

Alkyl carbamate-substituted &#x3b2;-lactones, process for their preparation, and pharmaceutical compositions containing them

Compounds having NEP-inhibitory activity, corresponding to the formula I in which

Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives

Compounds with neutral endopeptidase (NEP) inhibitory activity corresponding to the formula I ##STR1## in which R.sup.1 is a lower alkoxy-lower-alkyl group whose lower alkoxy radical is substituted by a lower alkoxy group, or a phenyl-lower-alkyl or phenyloxy-lower-alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or a naphthyl-lower-alkyl group,

Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid

Flavone-3-carboxylic acid compounds corresponding to the Formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent hydrogen, lower alkyl, halogen, hydroxy, or etherified or esterified hydroxy, and Z-R.sup.6 stands for a basically substituted alkoxy or amino group, as well as processes and intermediate products for their production. The compounds exhibit inflammation-inhibiting pharmacological activity.

3-flavone carboxylic acid compounds

Falvone-3-carboxylic acid compounds corresponding to the Formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent hydrogen, lower alkyl, halogen, hydroxy, or etherified or esterified hydroxy, and Z--R.sup.6 stands for a basically substituted alkoxy or amino group, as well as processes and intermediate products for their production. The compounds exhibit inflammation-inhibiting pharmacological activity.

Flavone-3-carboxylic acids compounds and pharmaceutical compositions

Growing community of inventors

Garbsen, Germany

Michael Wurl